Collagenase histiolyticum

Phase 1Small molecule

Collagenase histiolyticum is one of 6 small molecule programs targeting Esophageal stricture. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal StrictureActive, not recruiting

Esophageal StricturePhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Esophageal Stricture

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

2 2

Kenalog

Pulmicort

1 4

Decadron

AAspen Global Incorporated

Phase 2

1 5

Tranilast

NNuon Therapeutics, Inc.

Phase 2

1 6

Collagenase histiolyticum

UUniversity Hospital, Ghent

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal stricture1 trial

Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures

Terminated·UUniversity Hospital, Ghent·Phase 1·NCT03898661·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Collagenase histiolyticum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Collagenase histiolyticum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Collagenase histiolyticum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Ghent company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital, Ghent

Collagenase histiolyticum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal stricture1 trial

References

Drug Info

Quick Facts

Related News